Milestone Pharmaceuticals Inc
MIST1.840USD
-0.010-0.54%
Fechamento 11/04, 16:00（ET）Cotações atrasadas em 15 min
98.43MValor de mercado
PerdaP/L TTM
Mais detalhes de Milestone Pharmaceuticals Inc Empresa
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Informações de Milestone Pharmaceuticals Inc
Código da empresaMIST
Nome da EmpresaMilestone Pharmaceuticals Inc
Data de listagemMay 09, 2019
CEOMr. Joseph Oliveto
Número de funcionários33
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 09
Endereço420-1111 boul. Dr.-Frederik-Philips
CidadeMONTREAL
Bolsa de valoresNASDAQ Global Select Consolidated
PaísCanada
Código postalH4M 2X6
Telefone15143360444
Sitehttps://www.milestonepharma.com
Código da empresaMIST
Data de listagemMay 09, 2019
CEOMr. Joseph Oliveto
Executivos da empresa Milestone Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 30 de out
Atualizado em: qui, 30 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Trails Edge Capital Partners LP
6.27%
Simplify Asset Management Inc
3.33%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
2.11%
Outro
82.38%
Investidores
Investidores
Proporção
Trails Edge Capital Partners LP
6.27%
Simplify Asset Management Inc
3.33%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
2.11%
Outro
82.38%
Tipos de investidores
Investidores
Proporção
Investment Advisor
12.62%
Individual Investor
3.61%
Investment Advisor/Hedge Fund
3.03%
Hedge Fund
2.58%
Venture Capital
2.30%
Research Firm
2.16%
Bank and Trust
0.02%
Outro
73.68%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
99
19.30M
22.71%
-5.65M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Trails Edge Capital Partners LP
5.33M
6.27%
+5.33M
--
Jul 14, 2025
Simplify Asset Management Inc
990.00K
1.16%
+140.00K
+16.47%
Jun 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
RTW Investments L.P.
2.51M
2.95%
--
--
Jun 30, 2025
Propel Bio Management, LLC
1.79M
2.11%
+340.00K
+23.42%
Jun 30, 2025
Alta Fundamental Advisers LLC
1.40M
1.65%
-28.50K
-2.00%
Jun 30, 2025
BML Capital Management LLC
1.14M
1.34%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
817.82K
0.96%
-148.10K
-15.33%
Jun 30, 2025
TD Securities, Inc.
750.00K
0.88%
--
--
Jun 30, 2025
Lion Point Capital, L.P.
548.81K
0.65%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Simplify Propel Opportunities ETF
8.56%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
Proporção8.56%
SPDR S&P International Small Cap ETF
Proporção0.01%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
